TG Therapeutics (TGTX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of TG Therapeutics (TGTX)
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Key Insights
Critical company metrics and information
Share Price
$33.93Market Cap
$5.28 BillionTotal Outstanding Shares
155.67 Million SharesTotal Employees
319Dividend
No dividendIPO Date
December 14, 1995SIC Description
Pharmaceutical PreparationsHomepage
https://www.tgtherapeutics.com
Historical Stock Splits
If you bought 1 share of TGTX before April 30, 2012, you'd have 0.02 shares today.
Execution Date | Split Amount |
---|---|
April 30, 2012 | 1-for-56.25 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $134.60 Million |
Net Cash Flow From Operating Activities, Continuing | $-28.09 Million |
Net Cash Flow From Investing Activities, Continuing | $-61.58 Million |
Net Cash Flow From Operating Activities | $-28.09 Million |
Net Cash Flow From Financing Activities, Continuing | $134.60 Million |
Net Cash Flow From Investing Activities | $-61.58 Million |
Net Cash Flow | $44.93 Million |
Net Cash Flow, Continuing | $44.93 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations Before Tax | $-13.88 Million |
Benefits Costs and Expenses | $278.68 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income/Loss From Continuing Operations After Tax | $-14.36 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Earnings Per Share | $0.10 |
Selling, General, and Administrative Expenses | $146.49 Million |
Operating Income/Loss | $505000.00 |
Operating Expenses | $234.35 Million |
Net Income/Loss Attributable To Parent | $-14.36 Million |
Revenues | $264.79 Million |
Diluted Average Shares | $162.92 Million |
Income Tax Expense/Benefit | $479000.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-14.36 Million |
Gross Profit | $233.85 Million |
Net Income/Loss | $-14.36 Million |
Costs And Expenses | $265.30 Million |
Basic Average Shares | $145.73 Million |
Nonoperating Income/Loss | $-13.38 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Earnings Per Share | $0.10 |
Cost Of Revenue | $30.94 Million |
Research and Development | $87.87 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Assets | $148.40 Million |
Current Assets | $574.07 Million |
Liabilities | $393.86 Million |
Equity Attributable To Parent | $192.16 Million |
Equity | $192.16 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Noncurrent Liabilities | $268.74 Million |
Assets | $586.01 Million |
Current Liabilities | $125.11 Million |
Inventory | $84.67 Million |
Cash | $341.00 Million |
Liabilities And Equity | $586.01 Million |
Noncurrent Assets | $11.95 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.